Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Canada and EU may extend MRA (mutual recognition agreement) transition period:

This article was originally published in Clinica

Executive Summary

There may be a delay in the final implementation of the mutual recognition agreement (MRA) between Europe and Canada. The accord, which covers a number of sectors including medical devices, came into force on November 1 last year and a confidence building phase is now underway. This phase was expected to last 18 months. However, "an extension is likely as the implementation is complex", involving both the technical dossier review and quality systems, according to Dorothy Walker, the MRA co-ordinator for the Canadian Medical Devices Bureau.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT079898

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel